Thirty-three @entity1 with @entity1165 were referred for evaluation of their @entity943 using programmed electrical stimulation to guide antiarrhythmic therapy. @entity5354 , a new antiarrhythmic agent, was compared to @entity1818 in @entity1 with @entity1165 . @entity5354 was given intravenously, initially 1.0 mg/kg, then in 1 mg/kg increments to a maximum of 3.0 mg/kg, during electrophysiologic testing. The results were compared to @entity1818 , which was also administered intravenously to 1000 and then to 1500 mg. @entity5354 provided protection against @entity1165 induction in 16 of 33 @entity1 . The PR interval increased 13%, QRS duration widened 26%, and QTc interval was prolonged by 7%. There was a 9% fall in mean arterial blood pressure. @entity1818 prevented @entity1165 induction in 21 out of 31 @entity1 tested. The PR interval increased 11%, QRS duration widened 27%, and QTc interval prolonged by 8%. @entity5354 was given orally to 13 @entity1 for chronic treatment. Chronic oral @entity5354 therapy after a mean follow-up of 8.8 months caused a reduction of ventricular ectopy from 666 to 190 beats/hr. @entity1165 events decreased per Holter monitor recording from 6 to 0.6. @entity5354 therapy was discontinued in 5 of 13 @entity1 due to break-through @entity943 (nonsustained @entity1165 on Holter monitor and recurrence of symptoms). @entity5354 may be an effective antiarrhythmic agent in selected @entity1 .

Antiarrhythmic effects of XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1165 :: ('MESH:D017180', 'Disease') :: ['Ventricular tachycardia', 'ventricular tachyarrhythmias', 'ventricular tachycardia'] @entity1818 :: ('MESH:D011342', 'Chemical') :: ['procainamide', 'Procainamide'] @entity5354 :: ('MESH:C032151', 'Chemical') :: ['Cibenzoline', 'cibenzoline', 'Cibenzoline succinate'] @entity943 :: ('MESH:D001145', 'Disease') :: ['arrhythmias']
@entity5354 :: (MESH:C032151,Chemical) :: ['cibenzoline']
